Wegovy is not FDA-approved specifically for polycystic ovary syndrome (PCOS). Its approved uses are weight management in adults and adolescents with obesity or overweight, reducing cardiovascular risk in adults with established heart disease, and treating a form of fatty liver disease. PCOS does not appear anywhere in the prescribing information. That said, many women with PCOS are prescribed Wegovy or its lower-dose counterpart Ozempic off-label, and early research suggests real benefits for several hallmark features of the condition.
What Wegovy Is Actually Approved For
The FDA has cleared Wegovy for three categories of use, all alongside a reduced-calorie diet and increased physical activity. First, it can be prescribed for long-term weight management in adults with obesity (BMI of 30 or higher) or overweight (BMI of 27 or higher) with at least one weight-related condition such as high blood pressure or type 2 diabetes. That same weight-management indication extends to adolescents aged 12 and older with obesity. Second, it is approved to reduce the risk of major cardiovascular events, including heart attack and stroke, in adults who already have heart disease along with obesity or overweight. Third, it recently gained approval for a specific type of liver disease called metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced scarring.
None of these indications mention PCOS by name. However, many women with PCOS also meet the criteria for the weight-management indication, which means a doctor can prescribe Wegovy for weight loss even though the underlying reason is PCOS-related.
Why Doctors Prescribe It Off-Label for PCOS
PCOS and insulin resistance are tightly linked. The majority of women with PCOS have some degree of insulin resistance, which drives the body to produce excess androgens (hormones like testosterone). Those elevated androgens fuel many of the condition’s most frustrating symptoms: irregular periods, acne, excess hair growth, and difficulty losing weight. Any treatment that improves insulin sensitivity and promotes weight loss can, in theory, break that cycle.
Semaglutide, the active ingredient in Wegovy, is a GLP-1 receptor agonist. It mimics a gut hormone that slows digestion, reduces appetite, and helps the body manage blood sugar more effectively. For women with PCOS, those effects hit multiple problems at once: they make it easier to lose weight, they improve how the body responds to insulin, and they can shift cholesterol and blood sugar numbers in the right direction. There is also some evidence that GLP-1 drugs may improve ovulatory function, either through direct effects on the ovaries or as a downstream result of weight loss.
What the Research Shows So Far
Clinical studies on semaglutide in women with PCOS are still relatively small, but the results are encouraging. In one study published in Frontiers in Endocrinology, 25 women with PCOS and obesity took a weekly semaglutide injection alongside metformin and lifestyle changes for 16 weeks. Their median weight dropped from about 101 kg (223 lbs) to 92 kg (203 lbs), a loss of roughly 9 kg (20 lbs) in four months.
The hormonal changes were notable. Free testosterone levels fell significantly during treatment, dropping from a median of 6.16 to 4.12 nmol/L. That kind of reduction can translate into fewer androgenic symptoms over time, things like thinning of unwanted facial or body hair and more regular menstrual cycles. Fasting glucose, cholesterol, and post-meal blood sugar levels all improved as well.
The study also tracked what happened after the women stopped semaglutide but continued taking metformin. Two years later, they had regained about one-third of the weight they’d lost, but 21 out of 25 participants still weighed less than when they started. The testosterone reduction also held steady. The metabolic improvements in cholesterol and blood sugar, however, largely faded back toward their original levels. This suggests that while weight loss and hormonal benefits can persist for a meaningful period, ongoing treatment may be needed to maintain the full range of metabolic gains.
How PCOS Patients Can Access Wegovy
Because PCOS itself is not an approved indication, your path to a prescription typically runs through the weight-management criteria. If your BMI is 30 or higher, you qualify. If your BMI is 27 or higher and you have a weight-related condition (type 2 diabetes, high blood pressure, high cholesterol, or sleep apnea are common ones), you also qualify. Many women with PCOS meet one of these thresholds.
Insurance coverage can be a hurdle. Some plans cover Wegovy for weight management but require documentation of failed diet attempts or other prior treatments. Others exclude weight-loss medications entirely. Your provider may also consider prescribing Ozempic, which contains the same drug at a lower dose and is approved for type 2 diabetes, if insulin resistance or prediabetes is part of your clinical picture. The off-label landscape varies by insurer, so it is worth having a direct conversation with your doctor about which formulation and indication gives you the best chance of coverage.
Side Effects to Expect
The side effect profile for women with PCOS appears consistent with what is seen in the general population taking semaglutide. Nausea is the most common issue, especially during the dose-escalation phase when the injection strength is gradually increased over several months. Other gastrointestinal symptoms like diarrhea, constipation, and vomiting are also frequent but tend to lessen over time. Starting at a low dose and increasing slowly is the standard approach specifically to minimize these effects.
One consideration specific to PCOS: if semaglutide improves ovulatory function, you could become more fertile than you were before starting treatment. Women with PCOS who are not trying to conceive should discuss contraception with their provider, since semaglutide is not recommended during pregnancy.
How Wegovy Compares to Metformin for PCOS
Metformin has been the go-to off-label medication for PCOS for decades. It works primarily by reducing insulin resistance, which can modestly lower androgen levels and help restore ovulation. Weight loss on metformin alone tends to be limited, typically a few pounds at most.
Semaglutide produces substantially more weight loss and appears to drive larger improvements in testosterone and metabolic markers. The study described above used both drugs together, and the combination outperformed what is typically seen with metformin alone. When semaglutide was stopped, metformin on its own was enough to prevent full weight regain but not enough to maintain the metabolic improvements. This points to a complementary relationship: metformin provides a steady baseline of insulin-sensitizing support, while semaglutide delivers more dramatic weight and hormonal changes. Some providers now use both together for women with PCOS who have significant weight to lose or whose symptoms have not responded adequately to metformin alone.